New developments in bronchiectasis - The Lancet
2023年8月14日 · Genome sequencing in patients with idiopathic bronchiectasis might provide better insights into disease pathogenesis and opportunities for early prevention. Lung damage from bronchiectasis is irreversible and treatment options are scarce. The current guidelines are based on weak evidence from small studies, mainly from the USA and the UK.
Dundee research paves the way for breakthrough bronchiectasis …
2024年6月3日 · Millions of people living with bronchiectasis could potentially benefit from a breakthrough investigational therapy – brensocatib – following the announcement of new trial findings. The biopharmaceutical company Insmed has released the topline findings of its Phase 3 “ASPEN” study, indicating that participants given brensocatib ...
Non-CF Bronchiectasis Drug Brensocatib Gets FDA Breakthrough …
2020年6月15日 · Insmed’s brensocatib has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of adults with non-cystic fibrosis bronchiectasis. The designation is given to investigational compounds with early evidence of therapeutic potential on at least one clinically significant goal over existing ...
New thinking and a new direction in bronchiectasis
2024年8月20日 · This field looks set for paradigm shifting change, with the prospect of new treatments, better outcomes, and potentially disease modification. Bronchiectasis research has focused mainly on airway bacterial infection as a key driving mechanism, but the numerous trials of long-term antibiotic treatments, particularly inhaled antibiotics, have ...
Treating and Managing Bronchiectasis - American Lung Association
2024年10月29日 · The goal of bronchiectasis treatment is to treat any underlying conditions, prevent lung infections, remove excess mucus, and prevent flare-ups, also called exacerbations. This is done with a combination of medication, hydration and chest physical therapy.
Bronchiectasis: new therapies and new perspectives - The Lancet
2018年2月22日 · Development of new treatments for bronchiectasis has focused on modulating inflammatory processes, including targeting neutrophil, macrophage, T-cell, and epithelial function to reverse underlying disease processes
Advances in pharmacotherapy for bronchiectasis in adults
2023年5月9日 · Current pharmacotherapy aims to target at the five cardinal aspects of the vicious vortex: impaired airway defense, recurrent airway infections, inflammatory response and airway damage, and the underlying etiology. There is robust evidence for the use of maintenance low-dose macrolides in selected patients to reduce future exacerbation risks.
Bronchiectasis: new therapies and new perspectives - PubMed
In this Review, we discuss the mechanisms and potential roles of emerging therapies, including drugs that target airway and systemic inflammation, mucociliary clearance, and epithelial dysfunction.
Bronchiectasis — A Clinical Review | New England Journal of …
2022年8月10日 · This article reviews the presentation, diagnosis, and treatment of bronchiectasis, a syndrome of abnormal airways that results in chronic cough, sputum production, and respiratory impairment.
Bronchiectasis in adults: Treatment of acute and recurrent ... - UpToDate
2024年9月18日 · Instead, management of bronchiectasis is aimed primarily at treating exacerbations, controlling chronic infection and airway bleeding, reducing inflammation, and improving bronchial hygiene [1,2]. Surgical resection of affected areas may also be useful in selected patients.